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Introduction In Malaysia prostate cancer is ranked as fifth type of cancer among male. 
Unlike other cancers, prostate cancer is slow growth type of cancer; hence 
most patients may be asymptomatic despite having the disease. The burden 
associated with prostate cancer disease started from the diagnosis, the 
progress of disease and the varying impact of the available treatment options 
till the quality of life. The review focused on the disease and economic 
burden of prostate cancer disease towards country and patient personally. 
Methods A search was conducted to review related published studies on economic 
burden of the prostate cancer through PubMed/MEDLINE, Google Schorlar 
and Science Direct searching engines databases using keywords: Prostate 
cancer, economic burden and disease burden, treatment burden and treatment 
cost. For exploration on the burden itself, the keywords used were economic 
cost, mortality, morbidity, quality of life, treatment burden, palliative care. A 
review on the morbidity and mortality comparing global, Asian and Malaysia 
situation reviewed from previous review paper and online data. 
Conclusions Economic burden of prostate cancer include quality of life, treatment cost and 
palliative cost and palliative support care system. Development and 
improvise of the treatment facilities and equipment, strong knowledge and 
clinical training of staff in the treatment of cancer should be well planned in 
order to reduce the increasing burden of prostate cancer in Malaysia. 
Keywords Prostate cancer  - Burden of disease - Economic - Cost - Quality of life. 
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INTRODUCTION 
Cancer is indeed a serious health issue. According 
to data from Globocan 2012 stated 14.1 million 
new cancer cases reported with 8.2 million cancer 
deaths. The burden of cancer also included 32.6 
million people living with cancer within 5 years of 
diagnosis and estimated 5.3 million cancer deaths 
reported in the less developed regions. Men 
recorded 25% higher incidence rate of cancer than 
women in overall age standardized with 205 and 
165 per 100 000 respectively.1 According to the 
report prostate cancer is the fourth most common 
cancer combining both sexes with estimated 1.1 
million men been diagnosed in 2012 worldwide 
increasing from 513 000 diagnosed in year 2000.2 
By the year 2030 estimated that 1.7 million new 
cases of prostate cancer will be diagnosed with 
projection almost 500 000 death worldwide which 
bring it as the most common cancer in men in the 
future.3 Among men, statistic showed that prostate 
cancer ranked second most common cancer 
worldwide with age-standardized rate (ASR) of 
28.5 cases per 100 000 persons per year 
(International Agency for Research in Cancer, 
2008) and was the fourth most common cause of 
cancer death among men with ASR of 7.5 deaths 
per 100 000 person per year.1 
Malaysian National Cancer report 
(MNCR) 2007-2011 stated a total number of 103 
507 of new cancer cases been diagnosed over the 
period of 2007 till 2011 of which 46 794 (45.2%) 
reported in males. It makes the risk of males been 
diagnosed with cancer was 1 in 10 and for female 
was 1 in 9. The yearly cancer incidence in Malaysia 
has been estimated to be 30 000 per year with the 
prevalence approximately 90 000 to 100 000 at one 
time. Colorectal cancer (16.3%), Lung cancer 
(15.8%), Nasopharynx cancer (8.1%), Lymphoma 
(6.8%) and prostate cancer (6.7%) reported as the 
five most common cancers in males while females 
recorded breast (32.1%), colorectal (10.7%), cervix 
uteri (7.7%), ovary (6.1%) and lung (5.6%) in their 
top five most common cancer. Chinese has the 
highest age standardized incidence of cancer 
followed by Indian and Malay that reported 8.7, 5.8 
and 4.9 per 100 000 populations respectively by 
ethnicity.5, 6 
In 2014, Malaysian statistics reported 
prostate cancer was the fourth most common type 
of cancer that caused 1 186 number of incidence 
among male populations (WHO 2014).With an 
increase of life expectancy and aging population, 
the incidence of prostate cancer is expected to rise 
proportionately. In Malaysia the proportion 
population aged more than 60 years was 4.6% in 
1957, escalated to 5.7% in 1990 and projected to be 
9.8% in 2010.7 This study aimed to understand the 
economic burden of prostate cancer in Malaysia 
and comparing to other countries.  
 
METHODS 
A search conducted to examine published studies 
on disease and economic burden of the prostate 
cancer using MEDLINE / PubMed, Google 
Schorlar and Science Direct databases using 
keyword: “prostate cancer”, “economic cost”, 
“disease burden”, “treatment burden”, “treatment 
cost”. For exploration on the burden itself, the 
keywords used were “economic cost”, “mortality”, 
“quality of life”, “treatment burden”, “palliative 
care”. Then Boolean operator “OR” and “AND” 
been applied in combining search keywords for the 
study population, comparison, and outcomes in the 
title search from year 1995 onwards. The abstracts 
identified were screened based on the inclusion 
criteria. Full articles were reviewed then comparing 
with study done in other countries.  
 
RESULTS 
Morbidity and Mortality 
The 5-year relative survival rate of prostate cancer 
for all stages combines has increased from 68.3% 
to 99.9% in the past 25 year duration. The 10 year 
and 15 year relative survival rate reported as high 
as 97.8% and 91.4% respectively.8 These trends in 
survival rate have been attributed to a combination 
of multi factorial aspects such as early detection, 
improvement of effective treatment of localized 
and advanced disease, longer lead-time bias as 
early diagnosis falsely appears to prolong survival, 
and over diagnosis in cancer screening such as due 
to wide spread use of Prostate Specific Antigen 
(PSA) screening.9-11 However these trends in 
morbidity and mortality and outcomes are continue 
to differ across socio demographics, 
socioeconomic, racial and culture, and ethnic 
boundaries. There were few studies reported 
prostate cancer survivors in non-white populations 
with low economic status and education level were 
likely to have poorer quality of life with lower 
likelihood of survival rate.12-14 
Prostate cancer incidence has been in 
increasing trend during the past few decades in 
many Asian countries. WHO reported in 2012, the 
incidence rates were estimated at 10.5% and 4.5% 
in East and South-Central Asia respectively. 
Currently prostate cancer ranked the sixth most 
frequent cancer in Asian men. The highest 
incidence reported in Western Asia ranking second 
and the lowest in South-Central Asia ranking 
eighth in all cancer incidence. Report from China 
National Cancer Registry showed the incidence 
was 9.92 per 100 000 in 2009 while incidence in 
Korea documented escalation incidence from 8.4 in 
1999 to 24.4 per 100 000 population in 2011.15, 16 
Although in general the prostate cancer incidence 
was reported quite low comparing to western 
countries ; however with aggressive economic and 
socio-cultural changes, improvement life 
expectancy with urbanized lifestyles, the incidence 
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and mortality rates of prostate cancer in some 
Asian countries have shown a tremendous 
increasing trend in which was believed to be one of 
the serious healthcare and socio-economic problem 
in the future.17, 18  
In the year 2012, the overall average 
mortality rate of prostate cancer in Asian countries 
reported at 3.8 per 100 000 whereby countries with 
rapid economy development such as Japan, 
Singapore, and Korea had their prostate cancer 
mortality rate of 5, 4.5 and 4.6 per 100 000 
populations each. There were also variable trends 
of mortality seen in countries like China (Hong 
Kong), Kazakhstan and Korea. Countries like 
Israel, Kyrgyzstan and Uzbekistan had reported of 
declining trends of mortality while more stable 
mortality trends reported in Singapore and 
Tajikistan.18  
In Malaysia, Lim et al in 2008 had 
discussed that the annual mortality rate per 100 000 
people from prostate cancer has increased in the 
past decade by 93.7% since 1990, an average of 
4.1% a year with age specific incidence rise after 
age of 50 years old.5 By the year of 2030, prostate 
cancer incidence expected to increase to 1.7 million 
newly diagnosed cases with 499 000 deaths 
worldwide. By then prostate cancer will be known 
as the top most type of cancer in men in the future 
that contribute to 15% of all new cancer cases in 
men and it is predicted that 70% of all new cases of 
the prostate cancer occur in developed countries.15-
18 
 
Screening and Awareness Program 
Early detection and prompt treatment always be the 
main vision to improve the chances of cure in any 
type of cancer. Unfortunately delays in presentation 
for screening, diagnosis and treatment are 
commonly found among cancer patients especially 
prostate cancer. One of the initiatives done to 
overcome the late presentation is by providing 
prostate cancer screening such as stated in the 
Malaysian National Cancer Management Blueprint 
2008-2010. However due to lack of strong 
evidence regarding the advantages in benefit and 
cost especially in asymptomatic men, the mass 
population based screening for prostate cancer in 
Malaysia did not recommended.19, 20 Schersten et al 
in 1999 has stated that although the sensitivity and 
specificity of prostate specific antigen (PSA) gave 
good result towards prostate abnormalities but the 
test was not ideal enough due to high false positive 
and false negative rate. Besides that there was no 
study reported the PSA threshold or level that 
effectively able to differentiate between the 
presence and absence of prostate malignancy.20 As 
for now, the clinically practice criteria and 
abnormal digital rectal examination (DRE) were 
early predictors for prostate cancer before biopsy 
been done as the agent causes the development of 
prostate cancer is still unknown. It was supported 
by the relative risk of developing prostate cancer in 
first degree relatives was 2.5 folds, and 3.5 folds 
with two affected relatives.21 
Many studies have shown the mixed 
reviews though most researchers found a parallel 
association whereas higher level of education leads 
to recognition or awareness of the any disease. The 
good knowledge regarding prostate cancer 
screening also showed the rate of doing prostate 
screening is twice amount of respondents compared 
to group with low level of knowledge. Those with 
high formal education responded higher in the 
awareness and had undergone prostate cancer 
screening practice. Friends, media and workplace 
played important role in spreading the awareness. It 
is documented that media that reported on mortality 
and morbidity of prostate cancer to public will 
actually raising the awareness on disease to 
community. Thus, good knowledge of prostate 
cancer screening plays very important role to raise 
the awareness either by formal or informal 
education system.22  
While in Malaysia there was increment of 
prevalence prostate cancer with massive promotion 
where the age-standardized incidence of prostate 
cancer was 12 per 100 000 populations in 2005 
which higher than the incidence of 10.3 per 100 
000 population in 2003 however the prevalence 
seem decreasing to 6.2 in 2006 when there was less 
screening promotion undergone.5 
 
Economic Burden 
In general, prostate cancer management and 
treatment are depending to the stage of cancer 
itself. For prostate cancer with early stage, the 
treatment decision depended to the individualized 
approach such as hormonal therapy, prostatectomy, 
radical radiation or active surveillance based on 
age, comorbidities and side effect of treatment to 
the patients. As for more advanced stage of prostate 
cancer, the choice of palliative care, with androgen 
deprivation therapy with medical or surgical 
castration been always recommended treatment 
option according to National Comprehensive 
Cancer Network, NCCN 2012.23 Studies in United 
States had showed that the treatment of prostate 
cancer had brought a high economic and financial 
burden;  total cost of prostate cancer care was 
reported at about US$12 billion in 2010, increasing 
from US$10 billion in 2006, US$1.3 billion in 
1994 and projected rise to US$16 billion in 2020.24 
Another economic burden study by Stokes in 2011 
had also predicted a lifetime cost of US$110  520 
per person required for treatment based from the 
Surveillance Epidemiology and End Results 
(SEER) model analysis.25 It was supported by 
another study by Wilson et al that stated financial 
commitment in the prostate cancer management 
were US$7 740 which range from US$ 5 843 for 
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active surveillance to US$12 590 for hormonal 
therapy or androgen deprivation therapy while 
mean cumulative cost was US$ 42 570 over 5 years 
that range the least cost on active surveillance (US$ 
32 135) to the highest costs were associated with 
androgen deprivation therapy (US$ 69 244) for all 
risk groups.26  
In Malaysia, there was a study by Hooi in 
1996 stated that duration of admission of cancer 
patients in hospitals considered as burden of cancer 
to the country. In 1995, a study conducted in 
Penang Hospital reported significant inpatient 
burden or workload from the cancer patient 
admission. The hospital based study had showed 
that the average duration of admission of cancer 
patient in the hospital was 12.7 days (range 1-130 
days) that directly projected the need of many 
manpower from different discipline.27 This study 
almost similar to the annual statistics report of 
Department of Radiotherapy and Oncology of 
Hospital Kuala Lumpur in 1997 with average stay 
in hospital of 11.4 days for the cancer patients 
comparing to the ward stay of whole Hospital 
Kuala Lumpur of 5.2 days in the same year.5  
In 2013, Sharifah Ezat et al had discussed 
burden of cost on skeletal-related event (SRE) such 
as bone metastases at spine for advanced prostate 
cancer patient. As Ministry of Health Malaysia had 
reported that neoplasm contributed about 11.12% 
out of the ten principal causes in 2011, bone 
metastases in prostate cancer could bring 
significant financial effect to the healthcare system 
or country in providing extensive health facilities 
and resources.28 The study also supported by 
Bernad et al in 2011 that reported cancer patients 
also have a risk for high economic and financial 
burden compared with other patients with chronic 
comorbid as they may have higher out-of-pocket 
costs or medical expenses. The financial burden 
were significantly worse with metastases disease 
who are treated with palliative support care that 
depended on many factors such as patient`s 
underlying comorbid, daily activities, location of 
metastases, treating paramedic and physician, and 
also equipment available.29, 30 Based on study of 
health insurance claimed between year 2002 and 
2008 by Hagiwara et al in 2011 stated that bone 
metastases contributed to a 55% increase in 
average total monthly healthcare expenses or US$ 
12 780 per person year. Another issue of increment 
of cost burden is late diagnosis of bone metastases 
that implicate to more invasive and frequent 
investigations, which can result in increasing 
resource, equipment and manpower utilization due 
to complication and prolonged hospitalization.31 It 
was proven by model analysis of patients with 
metastatic breast cancers and prostate cancers study 
in Portugal that showed the diagnosis of bone 
metastases had brought a significant 19% to 106% 
increase in treatment financial costs while Penson 
stated that prostate specific antigen (PSA) 
progression would also contribute to a significant 
economic burden with disregard of baseline stage, 
Gleason grade and type of treatment.32, 33 Another 
study by George Institute for Global Health in 2015 
had stated that 45% of cancer patients may face 
financial catastrophe after a year of diagnosis. This 
situation worsen after one year of treatment started 
when reported 39% were not able to pay for 
medication, 35 % were not able to pay for medical 
consultation fees or tests, 22% were not able to pay 
for rent or mortgage and sadly 19% may actually 
stop treatment.  
Earlier study in year 2002 by Max et al 
stated economic burden of prostate cancer not only 
involving medical treatment such as cost of 
admission to the hospital, clinics follow ups, 
hormonal or chemotherapy drugs, palliative 
support care but also involving mortality costs in 
which is the estimate expected patient individual`s 
future salary or wages based on their age diagnosed 
till retire age. These calculations may also 
involving patient expected life expectancy and 
possibility in increment of salary in future age. In 
total the burden of prostate cancer calculated may 
reach till US$ 360 million which involving US$ 
180 million from direct health care cost and 
another US$ 180 million came from total loss of 
productivity due to premature death due to prostate 
cancer.34  
 
Quality of Life 
Generally quality of life means the state of 
wellbeing which consist of two main components 
that involving patient to undergo their daily 
activities including physical ability, psychological 
status, communications and social well-being and 
patient satisfaction towards functioning and control 
of the disease. Numbers of quality of life study 
found that disease and treatment related symptoms 
gave low level score and poor impact on cancer 
patients. The treatments itself gave significant 
impact to the quality of life especially those were 
diagnosed late in the advanced stage as their main 
priority treatment that include radical radiotherapy, 
chemotherapy and pain medications aimed to delay 
or avoid bone metastases and pain management 
that believed may able to improve patient daily 
activities and quality of life.35, 36  
Measuring patient quality of life provides 
information that may help prostate cancer patient 
evaluating their physical, psychological, social and 
functional abilities during and after treatment. 
Generally these prostate cancer patients were 
worried about the side effects of treatment and 
implications of prostate cancer in their lives. 
Although most of them may perform normal daily 
physical activities, some may still worried about 
their sexual function and ability to satisfy their 
sexual partner relationship. By measuring the 
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quality of life these prostate cancer patients are able 
to understand the complications and consequences 
of the disease from their treatments and also 
helping physicians to know patient`s acceptance 
towards treatment.37  
Study in Malaysia on quality of life 
among prostate cancer patients by Mohamad Rodi 
Isa in 2012 been done and reported that they were 
likely to develop anxiety disorder as they were 
repeatedly exposed to multiple investigations and 
treatment that potentially induced anxiety and fear 
during treatment such as monitoring of prostate 
specific antigen (PSA). However, anxiety level 
decreased with ongoing repeated investigations and 
increasing age. There were study reported that 
mean anxiety level had declined from 20% to 12% 
which include in reduction of psychomotor, 
agitation, weakness, fatigue and pessimism. The 
study also mentioned that those patients who had 
tolerated the cancer management and treatment will 
have low level on anxiety disorder. Mohamad Rodi 
also discussed that the physical health status and 
mental health status in Malaysia may be varied due 
to the ability of improvise and adaptation 
mechanism to the cancer.38 A study in Canada on 
health related quality of life (HRQOL) documented 
that the level varied among prostate cancer patients 
with different type of treatment that include radical 
prostatectomy, radiotherapy and brachytherapy. 
The study also reported that patients who 
undergone radiation therapy with early prostate 
cancer will have good urinary control and sexual 
function while brachytherapy had gave obstructive 
irritated implications to patients.39 
 
Palliative care  
Palliative care or supportive care may also cause 
economic burden as it needs a multidiscipline team 
to improve the quality of life of prostate cancer 
patients. This palliative care aimed to educate care 
giver or families with cancer pain management, 
prevention and relief of suffering due to cancer 
symptoms. Commonly practice palliative care 
usually based on three main objectives or goals 
which are improving morbidities due to prostate 
cancer disease, morbidities due to the treatment and 
quality of life after diagnosis.  
In Malaysia, palliative care program is 
usually initiated and organized either by 
government of private sector or non-governmental 
organizations (NGO) such as hospice home that 
include the training of medical doctors, nurses, 
medical assistants and public volunteers. Ideally 
the management cancer care patients after their 
discharge from hospital should be carried out by 
certified medical personnel either in the peripheral 
hospitals or their homes. These personnel must 
been trained in basic cancer care, ability to 
recognized and complications due to cancer or 
treatment and able to communicate with the 
oncologist that actually lead to tremendous amount 
of out of pocket money. Although the palliative 
care system in Malaysia quite established there is 
still area to improve including the limitation of 
palliative personnel to deliver best supportive care 
due to lack of knowledge such as the underuse of 
aqueous morphine in the severe cancer pain in 
advance stage of prostate cancer patients. Besides 
that it is necessary for the palliative care personnel 
to manage any morbidity caused by prostate cancer 
itself such as those patients with bone metastases, 
spinal cord compression, urinary obstruction and 
also any related psychological implications 
including depression, poor coping mechanism 
including intimacy issues.40  
Many literatures and randomized trial 
studies overwhelmingly support the establishment 
of palliative care in treating cancer especially in 
advanced stage. The studies believed that these 
palliative support care centers capable to improve 
quality of life including relieving symptoms, 
improved patient expectation and also able to 
reduce health care expenses.41, 42 There were trials 
by Temel and colleague that reported palliative 
supportive care implementation resulted significant 
longer median survival of 11.6 months comparing 
8.9 months (p-value 0.02) in patient without 
palliative care. Another study by Rabow also 
reported that prostate cancer patients who went 
palliative care intervention had statistically 
significant improvement in fatigue, anxiety, 
depression, quality of life and spiritual well-
being.40  
However, one of the main limitation of 
this palliative care program is late referrals due to 
lack of knowledge to recognize end life symptoms 
in cancer patients while Dalal et al stated that the 
barrier to this care was the name “palliative care” 
itself. It was proven after he managed to receive 
many consultations after he replaced the group`s 
name to “supportive care” that actually lead to 
shorter time of diagnosis to consultation.44  
One of the initiatives to empower 
palliative care, World Health Organization (WHO) 
had recommended that palliative care component to 
be part of national educational syllabus. In 
Malaysia, this initiative been applied to local 
medical universities that offer palliative care in 
their postgraduate courses of family medicine and 
nursing teaching programs while in hospital, 
regular workshops and seminars are being 
organized to the palliative care units to empower 
their knowledge and skills towards good quality of 
palliative support care.45 
 
DISCUSSION 
As prostate cancer is one of the commonest 
diagnosed malignancies in men, the burden of this 
disease is likely to increase. Although prostate 
cancer mortality rates are declining with the 5-year 
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survival rate for prostate cancer patients is reaching 
99%, 10-year survival is 91% and 15-year survival 
is 76%, the economic burden of disease treatment 
is growing fast. This growing economic burden is 
surely give big impact for Malaysia as developing 
country where health care expenditures need to 
compete with other sector such as social welfare, 
education and infrastructures. The economic 
burden of any disease can be divided to direct and 
indirect costs incurred by cancer patients. The 
direct costs include services for health care such as 
treatment, procedures, laboratory investigations, 
screening and health care professionals while 
indirect costs represent the reduced productivity 
associated with lost or impaired ability to work 
because of illness and the loss of economic 
productivity because of premature death.  
There are a lot of studies reported that 
most of economic burden in prostate cancer 
associated with direct cost as it occurred in elderly 
men. Health Canada estimates direct costs for all 
forms of cancer amounted to $3.2 billion, 
Netherlands reported for 5% to 6% of total 
healthcare budget of direct health care costs for all 
cancers in 1988 and Sweden estimated at 5.8% of 
all disease burden and approximately 25% of total 
costs for medical care were incurred during the first 
year after diagnosis.46 However the study reported 
that indirect cost burden of prostate cancer were 
relatively lower as most of the patient diagnosed at 
the age of more than 70 years old.46 The study 
analysis from a patient perspective and includes 
reimbursement payments made to physicians, 
facilities and other healthcare professionals for the 
medical services that were provided to cancer 
patients. Other components of the economic burden 
including out-of-pocket spending on direct medical 
care as well as the indirect costs associated with 
reduced productivity and lost work time for both 
caregivers and patients were not included in this 
study. These cost components have been shown to 




As for cost effectiveness the introduction of PSA 
screening seem to be speculative as it gave more 
economic burden due to increasing number of 
patients diagnosed with prostate cancer. Hence few 
strategies were identified such as treating those 
cancers which will become clinically significant 
would considerably reduce treatment costs. This is 
supported by Stokes et al that stated higher costs in 
the early stage of prostate cancer that comparing 
his finding with Riley.25, 46-47 
 
CONCLUSION 
In conclusion, the burden of prostate cancer in 
Malaysia is really worrying and be focused 
holistically. Multi sectoral agencies should work 
together in order to reduce the incidence rate, 
morbidities and mortality of prostate cancer. In 
order to improve the quality of life of cancer 
patients, policies that focused on cancer prevention, 
early screening and diagnosis, effective treatment, 
best palliative support care and rehabilitation must 
be revised and improved. More economic and 
costing studies should be done on economic burden 
of prostate cancer in order to understand the total 
burden of the prostate cancer disease in Malaysia. 
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